证券代码：002589 证券简称：瑞康医药 公告编号：2023-045 瑞康医药集团股份有限公司 关于实际控制人部分股份质押及质押展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人韩旭先 生的函告，获悉其收到中国证券登记结算有限责任公司股份质押登记证明，所持 有本公司的部分股份质押展期、部分股份已完成质押，具体事项如下： | | 是否为控 | | 占其所 | 占公 | 是否 | 是否 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质 | | 司总 | | 为补 | 质押起 | | 质押到 | 展期后 | | | 质押用 | | | 第一大股 | 押数量 | 持股份 | | 为限 | | | | | 质押到 | | 质权人 | | | 名称 | 东及其一 | （万股） | 比例 | 股本 | 售股 | 充 ...

Financial Performance - The company's revenue for Q3 2023 was ¥2,025,130,031.90, a decrease of 39.47% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥11,447,150.75, representing a decline of 646.64% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,242,407.50, an increase of 105.57% compared to the previous year[5]. - Total operating revenue for Q3 2023 was CNY 6,105,062,530.67, a decrease of 44.1% compared to CNY 10,896,716,818.79 in the same period last year[20]. - Net profit for Q3 2023 was CNY 27,832,019.60, a decline of 80.9% from CNY 145,362,681.81 in Q3 2022[21]. - The total comprehensive income for Q3 2023 was CNY 27,832,019.60, significantly lower than CNY 145,362,681.81 in the same quarter last year[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,427,544,905.61, down 4.93% from the end of the previous year[5]. - The company's total assets decreased to CNY 17,427,544,905.61 from CNY 18,331,074,646.82, a reduction of 4.9%[19]. - Total liabilities amounted to CNY 11,731,512,783.32, down from CNY 12,579,267,518.31, indicating a decrease of 6.8%[19]. - The equity attributable to shareholders of the parent company increased to CNY 5,483,430,853.83 from CNY 5,407,787,638.68, reflecting a growth of 1.4%[19]. Cash Flow - Operating cash flow net amount was ¥332,495,045.47, an increase of 2.13% year-to-date[5]. - Cash inflow from operating activities totaled 7,277,559,775.64 CNY, down from 13,674,133,744.92 CNY year-on-year[22]. - Net cash flow from operating activities was 332,495,045.47 CNY, slightly up from 325,546,433.95 CNY in the previous period[22]. - Cash inflow from investment activities was 1,041,094,767.33 CNY, compared to 1,975,130,880.55 CNY in the previous period[23]. - Net cash flow from investment activities increased to 439,775,610.96 CNY from 155,565,052.30 CNY year-on-year[23]. - Cash inflow from financing activities was 15,528,940,865.23 CNY, down from 17,644,956,563.09 CNY in the previous period[23]. - Net cash flow from financing activities showed a negative balance of -827,867,599.15 CNY, worsening from -335,170,334.57 CNY in the previous period[23]. - The ending balance of cash and cash equivalents was 431,546,196.65 CNY, down from 982,174,121.42 CNY in the previous period[23]. Expenses - The company reported a 43.97% decrease in operating income for the year-to-date period, totaling ¥610,506.25[11]. - The company experienced a 52.90% reduction in selling expenses, amounting to ¥37,553.35, due to decreased sales activities[11]. - Research and development expenses for Q3 2023 were CNY 10,177,007.27, slightly down from CNY 10,359,536.42 in the previous year[20]. - Cash paid for purchasing goods and services decreased by 41.58% to ¥625.79 million, reflecting reduced sales revenue[13]. - Cash paid to employees decreased by 52.65% to ¥21.49 million, attributed to a reduction in the scope of consolidation[13]. - Cash paid for taxes decreased by 70.68% to ¥11.73 million compared to the previous year[13]. Investments - Investment income increased by 59.49% to ¥41,651.21, attributed to gains from the divestiture of subsidiaries[12]. - The company reported an investment income of CNY 416,512,053.59, an increase from CNY 261,149,688.26 year-over-year[20]. - Cash received from investment income fell by 81.17% to ¥0.08 million due to lower returns from financial products[13]. - Long-term equity investments increased by 63.73% to ¥714.13 million compared to the beginning of the year[17]. Shareholder Information - The number of common shareholders at the end of the reporting period was 89,860[15]. - The company's basic earnings per share were -¥0.0076, a decrease of 642.86% year-on-year[5]. - Basic earnings per share decreased to 0.0128 from 0.0406 in the previous period[22]. Audit and Reporting - The company did not undergo an audit for the third quarter report[24]. - The report was issued by the board of directors on October 31, 2023[25].

山东乾元律师事务所·法律意见书 关于瑞康医药集团股份有限公司 2023 年第三次临时股东大会的律师见证法律意见书 致：瑞康医药集团股份有限公司 山东乾元律师事务所（以下简称"本所"）接受贵公司的委托，指派 时晓旸、衣超律师（以下简称"本所律师"）出席贵公司于 2023 年 9 月 15 日下午 15 点在位于山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室举行 的 2023 年第三次临时股东大会（以下简称"本次股东大会"），并根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》及《上市公司股东大会规则》等法律法规及规范性文件和《瑞康医药 股份集团有限公司章程》（以下简称"《公司章程》"）的规定，就本次 股东大会的召集与召开程序、出席会议人员的资格和召集人的资格、审议 事项以及表决方式、表决程序、表决结果依法进行见证，并出具法律意见。 为出具本法律意见书，本所律师审查了贵公司提供的以下文件，包括: 1、贵公司的《公司章程》； 2、贵公司于 2023 年 8 月 29 日召开的第五届董事会第三次会议决议； 3、贵公司于 2023 年 8 月 30 日在《证券时报》、《中国证券报》 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-043 瑞康医药集团股份有限公司 2023 年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 一、 重要提示 本次股东大会召开期间没有增加、否决或变更议案的情况发生。本次股东大 会不涉及变更前次股东大会决议的情况。 二、 会议通知情况 《瑞康医药集团股份有限公司关于召开 2023 年第三次临时股东大会的通知》 于 2023 年 8 月 30 日在《证券时报》、《中国证券报》、《证券日报》、《上海 证券报》和巨潮资讯网上已经披露。 三、 会议召开基本情况 参加表决的股东及股东代理人共 22 人，代表股份 191,011,907 股，占公司有 表决权股份总数 12.6943%。其中： 1、会议召集人：公司董事会 2、会议时间：2023 年 9 月 15 日（星期五）下午 15:00 3、会议召开地点：山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 4、会议主持人：董事长、总裁韩旭先生 5、会议召开方式：现场会议结合网络投票方式 6、本次会议的召集、召开符合《公司法 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥4,079,932,498.77, a decrease of 45.97% compared to ¥7,551,070,413.29 in the same period last year[26]. - The net profit attributable to shareholders was ¥30,667,269.81, down 48.01% from ¥58,990,871.57 year-on-year[26]. - The net cash flow from operating activities was ¥178,680,614.05, representing a decline of 35.48% compared to ¥276,926,857.47 in the previous year[26]. - The basic earnings per share decreased by 47.96% to ¥0.0204 from ¥0.0392 in the same period last year[26]. - The total operating revenue for the first half of 2023 was CNY 4,079,932,498.77, a decrease of 45.97% compared to the same period last year[72]. - The company reported a net profit of CNY 41,586,431.75 for the first half of 2023, a decrease of 69.9% compared to CNY 138,001,790.94 in the first half of 2022[174]. - The total comprehensive income for the first half of 2023 was CNY 21,903,332.33, significantly lower than CNY 92,914,535.85 in the same period of 2022[178]. - The company reported a long-term investment of CNY 435.95 million, unchanged from the previous period, indicating stability in investment strategy[165]. Assets and Liabilities - Total assets at the end of the reporting period were ¥18,281,209,924.56, a slight decrease of 0.27% from ¥18,331,074,646.82 at the end of the previous year[26]. - The company's total liabilities decreased to CNY 13,802,912,315.42 in the first half of 2023 from CNY 15,055,784,416.68 in the previous year, a reduction of 8.3%[173]. - Cash and cash equivalents increased to CNY 6,179,217,668, accounting for 33.80% of total assets, up from 29.13% at the end of the previous year[76]. - The company's current assets increased to CNY 13.18 billion from CNY 12.82 billion, primarily driven by an increase in cash and cash equivalents, which rose to CNY 6.18 billion from CNY 5.34 billion[164]. - The total liabilities to assets ratio stands at approximately 68.3%, indicating a relatively high leverage level[166]. Revenue by Segment - The pharmaceutical and medical device distribution segment achieved revenue of 3.566 billion yuan during the reporting period[44]. - The IVD segment achieved revenue of 226 million yuan during the reporting period[46]. - The academic services segment generated revenue of 34.79 million yuan, serving over 300 medical institutions[50][49]. - The digital healthcare segment reported revenue of 37.55 million yuan, focusing on rational drug management and AI-driven solutions[53]. - The pharmaceutical logistics segment earned revenue of 16.36 million yuan, providing third-party logistics services and cold chain solutions[55]. - The traditional Chinese medicine segment realized revenue of 169 million yuan, emphasizing innovation in TCM products and services[60]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for this period[6]. - The company is focusing on optimizing its distribution product structure and accelerating the development of its own medical devices and traditional Chinese medicine products[42]. - A strategic cooperation agreement was signed between the company and two other firms to enhance market penetration and service capabilities in the East China region[43]. - The company aims to enhance its strategic focus on traditional Chinese medicine, including the development of innovative products and commercialization[61]. - The company is actively pursuing new business projects, including high-end medical devices and traditional Chinese medicine innovations, despite facing potential profitability risks[90]. Market and Industry Outlook - The company faces risks related to industry competition, management, market conditions, and national policies[5]. - The future goal for the pharmaceutical distribution industry is to cultivate 1-3 enterprises with over 500 billion yuan in revenue and 5-10 enterprises with over 100 billion yuan by 2025[35]. - The government aims to establish a high-quality and efficient traditional Chinese medicine service system by 2025, enhancing the level of disease prevention and treatment[38]. - The government plans to expand the coverage of centralized procurement to include most drugs used in medical institutions, ensuring reasonable and stable drug prices[36]. Corporate Governance and Social Responsibility - The company emphasizes its commitment to social responsibility and sustainable development[104]. - The company has established a governance structure to protect shareholder rights and ensure compliance with relevant laws[105]. - The company actively engages with investors to enhance communication and trust[106]. - The company promotes energy conservation and environmental protection, implementing a system for energy-saving goals and encouraging a culture of resource conservation among employees[114]. Human Resources and Employee Engagement - The company has developed a comprehensive human resources management system, including recruitment, training, and performance evaluation, to ensure efficient use of talent[110]. - The company established "Ruikang Academy" to enhance employee training, focusing on market expansion and management innovation to support rapid business growth[108]. - The company is focusing on human resource development to meet the increasing demand for skilled professionals in its transformation process[91]. Risks and Challenges - The company faced risks related to policy changes in the healthcare sector, impacting pricing and procurement strategies[88]. - Management risks are being addressed through dynamic adjustments to strategic planning and operational management improvements[92]. - The management has indicated a cautious outlook for the remainder of the year, anticipating challenges in the market environment[189].

证券代码：002589 证券简称：瑞康医药 公告编号：2023-037 瑞康医药集团股份有限公司 二、被担保人基本情况 关于公司及子公司担保额度预计的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2023 年 8 月 29 日召开第五届董事会第三次会议审议通过了《关于公司及子公司担保额度 预计的议案》，同意公司为合并报表范围内子公司（以下简称"子公司"）提供 担保、子公司互相担保额度总计不超过人民币 250,000 万元，其中向资产负债 率为 70%以上的担保对象的担保额度为不超过 125,000 万元，向资产负债率为 70%以下的担保对象的担保额度为不超过 125,000 万元。本次担保事项尚需提交 2023 年第三次临时股东大会审议，适用期限为 2023 年第三次临时股东大会审 议通过后两年内。 一、担保情况概述 为满足公司及子公司正常的生产经营需要，确保资金流畅通，同时加强公司 及子公司对外担保的日常管理，增强公司及子公司对外担保行为的计划性和合理 性，公司拟为合并报表范围内子公司提供担保、 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-038 瑞康医药集团股份有限公司 第五届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）第五届董事会 第三次会议通知于 2023 年 8 月 24 日以书面形式发出，2023 年 8 月 29 日上午在 烟台市芝罘区凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会议 由董事长韩旭先生主持，会议应出席董事 9 名，实际出席董事 9 名，公司监事列 席会议。本次会议的召开符合《中华人民共和国公司法》等法律、法规和《公司 章程》的规定。本次会议经有效表决，形成如下决议： 一、审议通过《关于公司及子公司担保额度预计的议案》 二、审议通过《关于聘任公司董事会秘书、副总裁的议案》 为完善公司治理结构，根据《中华人民共和国公司法》和《瑞康医药集团股 份有限公司章程》的规定，经董事长提名、董事会提名委员会审核，拟聘任李喆 先生为公司董事会秘书、副总裁，任期自本次董事会审议通过之日起至本届董事 会任期届满之日止。 ...

瑞康医药集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：瑞康医药集团股份有限公司 单位：人民币万元 | | | 占用方与上 | 上市公司核 | 2023 年期初 | 2023 年半年 | 2023 年半年 | 2023 年半年 | 2023 年半年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | 资金占用方 | 市公司的关 | 算的会计科 | 往来资金余 | 度往来累计 | 度往来资金 | 度偿还累计 | 度末往来资 | 占用形 | 占用性质 | | 金占用 | 名称 | | | | 发生金额 | 的利息(如 | | | 成原因 | | | | | 联关系 | 目 | 额 | (不含利息) | 有) | 发生金额 | 金余额 | | | | 现大股东及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 小计 | | | | 0.00 | 0.00 | 0.00 | 0.00 | ...